Vertex Pharmaceuticals (WBO:VRTX) 10-Year RORE % : 20.23% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:VRTX Vertex Pharmaceuticals Inc WBO:VRTX
90 GF Score
Price €419.00
GF Value €440.77
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals 10-Year RORE %?

Vertex Pharmaceuticals WBO:VRTX -1.35% 90 10-Year RORE % is 20.23 as of Mar. 2026. GuruFocus rates WBO:VRTX with a GF Score™ of 90/100 and a GF Value™ of €440.77 (Fairly Valued). The stock has 5 warning signs investors should review. Among 615 Biotechnology companies, Vertex Pharmaceuticals ranks better than 88.78% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Vertex Pharmaceuticals's 10-Year RORE % for the quarter that ended in Mar. 2026 was 20.23%.

The industry rank for Vertex Pharmaceuticals's 10-Year RORE % or its related term are showing as below:

WBO:VRTX's 10-Year RORE % is ranked better than
88.78% of 615 companies
in the Biotechnology industry
Industry Median: -6.37 vs WBO:VRTX: 20.23

Vertex Pharmaceuticals  (WBO:VRTX) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Vertex Pharmaceuticals 10-Year RORE % Related Terms


Vertex Pharmaceuticals 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals 10-Year RORE % Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.27 40.03 31.18 -0.02 21.22

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.19 24.32 22.35 21.22 20.23

WBO:VRTX vs REGN, ALNY, RVMD: 10-Year RORE % Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals 10-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's 10-Year RORE % falls into.


WBO:VRTX
90GF Score
Vertex Pharmaceuticals Inc WBO:VRTX
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals 10-Year RORE % Calculation

Vertex Pharmaceuticals's 10-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( 14.485-0.675 )/( 68.276-0 )
=13.81/68.276
=20.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of 20.23 mean?
Vertex Pharmaceuticals (WBO:VRTX) has a 10-Year RORE % of 20.23 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Vertex Pharmaceuticals and its competitors. According to the industry distribution chart, Vertex Pharmaceuticals ranks #69 out of 615 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Vertex Pharmaceuticals' 10-Year RORE % too high?
Vertex Pharmaceuticals' current 10-Year RORE % is 20.23. Based on the distribution chart, Vertex Pharmaceuticals ranks #69 out of 615 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vertex Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' 10-Year RORE % compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #69 out of 615 companies for 10-Year RORE %. This places Vertex Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Biotechnology company?
A good 10-Year RORE % depends on the Biotechnology industry context. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current 10-Year RORE % is 20.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €440.77, compared to a current price of €419.00 — trading 4.9% below its estimated fair value. The current 10-Year RORE % is 20.23. Vertex Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current 10-Year RORE % is 20.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €419.00 is trading 4.9% below its estimated GF Value™ of €440.77. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for WBO:VRTX:

  • 10-Year RORE %: 20.23
  • GF Value™: €440.77 vs. price of €419.00 (4.9% below fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
90GF Score

Get the complete analysis for WBO:VRTX

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€419.00
Price
€440.77
GF Value